Market revenue in 2022 | USD 270.2 million |
Market revenue in 2030 | USD 684.5 million |
Growth rate | 12.3% (CAGR from 2022 to 2030) |
Largest segment | Sickle cell disease |
Fastest growing segment | Sickle cell disease |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Thalassemia, Sickle cell disease, Other Hb Variants |
Key market players worldwide | Sangamo Therapeutics Inc, Global Blood Therapeutics, Bluebird bio Inc, Emmaus Life Sciences Inc, Pfizer Inc, Novartis AG ADR, Prolong Pharmaceuticals, Bioverativ, Gamida Cell, Bristol-Myers Squibb Co |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hemoglobinopathies market will help companies and investors design strategic landscapes.
Sickle cell disease was the largest segment with a revenue share of 62.47% in 2022. Horizon Databook has segmented the Canada hemoglobinopathies market based on thalassemia, sickle cell disease, other hb variants covering the revenue growth of each sub-segment from 2018 to 2030.
Carrier screening for SCD, thalassemia, and other hemoglobinopathies is increasing in Canada. Organizations such as Canadian Hematology Society, Sickle Cell Disease Association of Canada (SCDAC), Thalassemia Foundation of Canada, Canadian Hemoglobinopathy Association, and Sickle Cell Association of Ontario are actively involved in promoting awareness about disorders in Canada through workshops, counseling programs, and collaborations.
In addition, various programs by SCDAC, such as Sickle Cell Awareness Month September and promotion of newborn screening, are anticipated to drive market growth in the country. However, as of 2018, over 5,000 Canadians were suffering from SCD, and an estimated 120 babies are born with SCD every year. These factors are expected to drive the market growth during the forecast period.
Moreover, research grant programs have been launched to encourage academic institutions to conduct clinical research on these disorders. For instance, in November 2017, SCDAC and Pfizer Canada launched the National Research Program for SCD to provide grants for promising research related to SCD and comorbidities associated with the disorder.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada hemoglobinopathies market , including forecasts for subscribers. This country databook contains high-level insights into Canada hemoglobinopathies market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account